Omega Therapeutics (NASDAQ: OMGA), a development-stage biotechnology company, announced on Friday that it has named Joshua Reed as its new Chief Financial Officer, effective 23 May 2022.
Reed has served as Chief Financial Officer of Aldeyra Therapeutics and has held various finance roles of increasing responsibility at Bristol-Myers Squibb. He has also worked at JP Morgan Chase, Credit Suisse First Boston, and Chase Manhattan Bank.
The new Financial Officer holds a Bachelor of Science in Finance from Rutgers University and Master of Business Administration from the University of Michigan.
Bioforum, The Data Masters names new President
VolitionRx names new Chief Medical Officer
Quotient Sciences announces new appointments
Syndax Pharmaceuticals names new chief commercial officer
Everest Medicines names new chief medical officer and chief product officer
D3 Bio names new independent board member
Rigel Pharmaceuticals names new executive vice president and chief medical officer
Telix Pharmaceuticals names new group chief operating officer